Anti-angiogenesis therapies: their potential in cancer management

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for both normal development and tumor growth.
• Tumor angiogenesis provides essential nutrients and oxygen, facilitating cancer progression.
• Traditional cancer treatments like chemotherapy and radiation have limitations, driving the need for novel therapeutic strategies.

Purpose of the Study:

• To review the role and mechanisms of angiogenesis inhibitors in cancer treatment.
• To discuss currently approved angiogenesis inhibitors and their clinical applications.
• To highlight promising new agents and vascular disrupting agents in clinical trials.

Main Methods:

• Review of scientific literature on angiogenesis inhibitors.
• Analysis of mechanisms of action for approved and investigational drugs.
• Discussion of clinical trial data and evidence for efficacy and safety.

Main Results:

• Four drugs (Bevacizumab, Sunitinib, Sorafenib, Thalidomide) are approved for cancer treatment, targeting pathways like VEGF and bFGF.
• Bevacizumab neutralizes vascular endothelial growth factor (VEGF).
• Sunitinib and Sorafenib inhibit tyrosine kinase receptors; Thalidomide affects bFGF activity.
• Emerging agents like Aflibercept (VEGF-trap) and vascular disrupting agents show potential.

Conclusions:

• Angiogenesis inhibitors represent a significant advancement in cancer therapy.
• These agents offer synergistic effects with conventional treatments and distinct toxicity profiles.
• New therapeutic strategies targeting tumor vasculature hold promise for transforming cancer management.